The development of immunotherapy in older adults: new treatments, new toxicities?
C Helissey, C Vicier, S Champiat - Journal of geriatric oncology, 2016 - Elsevier
Monoclonal antibodies targeting immune checkpoint molecules CTLA-4, PD-1 or PD-L1 are
emerging as promising anticancer therapeutics in multiple cancer subtypes resulting in
remarkable and long-lasting clinical responses. These immune checkpoint blockers (ICBs)
have already obtained approval for the treatment of patients with metastatic melanoma,
advanced/refractory non-small cell lung cancer and renal cell cancer. ICBs enhance
immune responses against cancer cells but can also lead to inflammatory side effects called …
emerging as promising anticancer therapeutics in multiple cancer subtypes resulting in
remarkable and long-lasting clinical responses. These immune checkpoint blockers (ICBs)
have already obtained approval for the treatment of patients with metastatic melanoma,
advanced/refractory non-small cell lung cancer and renal cell cancer. ICBs enhance
immune responses against cancer cells but can also lead to inflammatory side effects called …
